Publications
All EurFMT members work as independent researchers to provide a solid evidence base for the use of microbiome therapies. We here mention relevant and recent publications. The list is not exhaustive, and for further information on relevant publications, please refer to the institutional contact information and websites of the collaboration partners and steering committee members.
EurFMT consensus papers, letters and guidelines1-14
1. Porcari S, Mullish BH, Asnicar F, et al. International consensus statement on microbiome testing in clinical practice. Lancet Gastroenterol Hepatol 2025;10:154-167.
2. Hvas CL, Keller J, Baunwall SMD, et al. European academic faecal microbiota transplantation (EurFMT) network: improving the safety and quality of microbiome therapies in Europe. Microb Health Dis 2023;5:954-964.
3. Ianiro G, Mullish BH, Iqbal TH, et al. Minimising the risk of monkeypox virus transmission during faecal microbiota transplantation: recommendations from a European expert panel. Lancet Gastroenterol Hepatol 2022;7:979-980.
4. Keller JJ, Ooijevaar RE, Hvas CL, et al. A standardised model for stool banking for faecal microbiota transplantation: a consensus report from a multidisciplinary UEG working group. United European Gastroenterol J 2021;9:229-247.
5. Ianiro G, Mullish BH, Hvas CL, et al. SARS-CoV-2 vaccines and donor recruitment for FMT. Lancet Gastroenterol Hepatol 2021;6:264-266.
6. Baunwall SMD, Terveer EM, Dahlerup JF, et al. The use of faecal microbiota transplantation (FMT) in Europe: A Europe-wide survey. Lancet Reg Health Eur 2021;9:100181.
7. Terveer EM, Vendrik KE, Ooijevaar RE, et al. Faecal microbiota transplantation for Clostridioides difficile infection: Four years’ experience of the Netherlands Donor Feces Bank. United European Gastroenterol J 2020:2050640620957765.
8. Ianiro G, Mullish BH, Kelly CR, et al. Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic. Gut 2020;69:1555-1563.
9. Hvas CL, Baunwall SMD, Erikstrup C. Faecal microbiota transplantation: A life-saving therapy challenged by commercial claims for exclusivity. EClinicalMedicine 2020;24:100436.
10. Keller JJ, Vehreschild MJ, Hvas CL, et al. Stool for fecal microbiota transplantation should be classified as a transplant product and not as a drug. United European Gastroenterol J 2019;7:1408-1410.
11. Jørgensen SMD, Hvas CL, Dahlerup JF, et al. Banking feces: a new frontier for public blood banks? Transfusion 2019;59:2776-2782.
12. Cammarota G, Ianiro G, Kelly CR, et al. International consensus conference on stool banking for faecal microbiota transplantation in clinical practice. Gut 2019;68:2111-2121.
13. Terveer EM, van Beurden YH, Goorhuis A, et al. How to: Establish and run a stool bank. Clin Microbiol Infect 2017;23:924-930.
14. Konig J, Siebenhaar A, Hogenauer C, et al. Consensus report: faecal microbiota transfer – clinical applications and procedures. Aliment Pharmacol Ther 2017;45:222-239.
Evidence for the effect of FMT in Clostridioides (Clostridium) difficile infection15-24
15. Porcari S, Baunwall SMD, Occhionero AS, et al. Fecal microbiota transplantation for recurrent C. difficile infection in patients with inflammatory bowel disease: A systematic review and meta-analysis. J Autoimmun 2023:103036.
16. Baunwall SMD, Hansen MM, Andreasen SE, et al. Donor, patient age and exposure to antibiotics are associated with the outcome of faecal microbiota transplantation for recurrent Clostridioides difficile infection: A prospective cohort study. Aliment Pharmacol Ther 2023;58:503-515.
17. Baunwall SMD, Lee MM, Eriksen MK, et al. Faecal microbiota transplantation for recurrent Clostridioides difficile infection: An updated systematic review and meta-analysis. EClinicalMedicine 2020;29-30:100642.
18. Peri R, Aguilar RC, Tuffers K, et al. The impact of technical and clinical factors on fecal microbiota transfer outcomes for the treatment of recurrent Clostridioides difficile infections in Germany. United European Gastroenterol J 2019;7:716-722.
19. Hvas CL, Jørgensen SMD, Jørgensen SP, et al. Fecal microbiota transplantation is superior to fidaxomicin for treatment of recurrent Clostridium difficile infection. Gastroenterology 2019;156:1324-1332.
20. Satokari R, Mattila E, Kainulainen V, et al. Simple faecal preparation and efficacy of frozen inoculum in faecal microbiota transplantation for recurrent Clostridium difficile infection–an observational cohort study. Aliment Pharmacol Ther 2015;41:46-53.
21. Cammarota G, Masucci L, Ianiro G, et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther 2015;41:835-43.
22. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013;368:407-15.
23. Mattila E, Uusitalo-Seppala R, Wuorela M, et al. Fecal transplantation, through colonoscopy, is effective therapy for recurrent Clostridium difficile infection. Gastroenterology 2012;142:490-6.
24. Paaske SE, Baumwall SMD, Rubak T, et al. Real-world Effectiveness of Fecal Microbiota Transplantation for First or Second Clostridioides difficile Infection. Clin Gastroenterol Hepatol 2024.
Methodological considerations in FMT25-27
25. Hansen MM, Rågård N, Andreasen PW, et al. Encapsulated donor faeces for faecal microbiota transplantation: the Glyprotect protocol. Therap Adv Gastroenterol 2024;17:17562848241289065.
26. Hocking L, Ianiro G, Leong RW, et al. Faecal microbiota transplantation for recurrent C. difficile infections: challenges and improvement opportunities for clinical practice and healthcare systems. Aliment Pharmacol Ther 2023;57:549-564.
27. McCune VL, Quraishi MN, Manzoor S, et al. Results from the first English stool bank using faecal microbiota transplant as a medicinal product for the treatment of Clostridioides difficile infection. EClinicalMedicine 2020:100301.
National clinical guidelines28, 29
28. Mullish BH, Merrick B, Quraishi MN, et al. The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridioides difficile infection and other potential indications: second edition of joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines. J Hosp Infect 2024;148:189-219.
29. Baunwall SMD, Dahlerup JF, Engberg JH, et al. Danish national guideline for the treatment of Clostridioides difficile infection and use of faecal microbiota transplantation (FMT). Scand J Gastroenterol 2021;56:1056-1077.
Revision date: 28.1.2025